LCM
ATOS icon

Laurion Capital Management’s Atossa Therapeutics ATOS Stock Holding History

Laurion Capital Management’s Portfolio ATOS Stock Details ATOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-148,387
Closed -$4.01M – 565
2024
Q1 		$4.01M Hold
148,387
– – 0.03% 279
2023
Q4 		$1.96M Hold
148,387
– – 0.02% 298
2023
Q3 		$1.64M Hold
148,387
– – 0.01% 346
2023
Q2 		$2.8M Hold
148,387
– – 0.02% 295
2023
Q1 		$1.61M Hold
148,387
– – 0.01% 282
2022
Q4 		$1.18M Hold
148,387
– – 0.01% 322
2022
Q3 		$1.85M Hold
148,387
– – 0.01% 332
2022
Q2 		$2.43M Buy
+148,387
New +$2.34M 0.04% 216

Other funds holding ATOS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Laurion Capital Management's ATOS Position: Q2 2024 in Review

Laurion Capital Management sold out of Atossa Therapeutics (ATOS) in Q2 2024, closing a stake of 148,387 shares — an estimated $4.01M sold.

Laurion Capital Management first reported a position in ATOS in Q2 2022 and held it in 8 quarters. The position peaked at $4.01M in Q1 2024. 77 funds tracked by Wall St. Rank hold ATOS as of Q2 2024.

  • Laurion Capital Management reported no remaining Atossa Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Laurion Capital Management sold 148,387 Atossa Therapeutics shares in Q2 2024, an estimated $4.01M.
  • Laurion Capital Management first reported a position in Atossa Therapeutics in Q2 2022 and held it in 8 quarters.
  • Laurion Capital Management's Atossa Therapeutics position peaked at $4.01M in Q1 2024.
  • 77 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q2 2024.

Based on Laurion Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.